Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages (MacFibOsis)

Rennes University Hospital

Status

Completed

Conditions

History of Exposure to Silica or Asbestosis

Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases

Treatments

Biological: Blood sample

Biological: Blood collection

Study type

Interventional

Funder types

Other

Identifiers

NCT04473742

35RC20_8878_MacFibOsis

Details and patient eligibility

About

Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MDM from healthy donors.

Full description

Patients with a proven history or current exposure will have 4 EDTA tubes drawn, approximately 24mL of fresh whole blood for efferocytosis assessment and :

2 x 6mL serum tubes for the assessment of Antinuclear Antibody (ANA) positivity, serum high-mobility group box 1 (HMGB1) and osteopontin for patients exposed to asbestos 1 x 6mL serum tube for serum HMGB1 and osteopontin for patients exposed to silica

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient older than 18 Yo
Addressed to the department of occupational disease
With a history of asbestosis or silica exposure evaluated by a dedicated questionnaire and a throughout examination of the history of occupations, according to standard procedures for the follow-up of at risk workers.
Persons who received an oral and written information on the protocol and signed the informed consent form

Exclusion criteria